Patents Examined by Sean R. McGarry
-
Patent number: 7645732Abstract: Methods and compositions are provided to inhibit release of HCV from an HCV-infected cell by contacting the cell with a VLDL assembly inhibitor, and detecting a resultant inhibition of HVC release from the cell. The methods can be used to decrease serum viremia of an HCV-infected person.Type: GrantFiled: January 24, 2007Date of Patent: January 12, 2010Assignee: Board of Regents, The University of Texas SystemInventors: Jin Ye, Fang Sun, Hua Huang, Michael J. Gale
-
Patent number: 7645744Abstract: RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in particularly in diseases such as diabetic retinopathy, age related macular degeneration and many types of cancer.Type: GrantFiled: January 26, 2009Date of Patent: January 12, 2010Assignee: The Trustees of the University of PennsylvaniaInventors: Samuel Jotham Reich, Enrico Maria Surace, Michael J. Tolentino
-
Patent number: 7638324Abstract: The invention provides Bcl-G polypeptides and encoding nucleic acids. Bcl-G polypeptides include Bcl-GL and Bcl-GS. The invention also provides mouse Bcl-G. The invention also provides vectors containing Bcl-G nucleic acids, host cells containing such vectors, Bcl-G anti-sense nucleic acids and related compositions. The invention additionally provides Bcl-G oligonucleotides that can be used to hybridize to or amplify a Bcl-G nucleic acid. Anti-Bcl-G specific antibodies are also provided. Further provided are kits containing Bcl-G nucleic acids or Bcl-G specific antibodies. Such kits and reagents can be used to diagnose cancer, monitor response to therapy, or predict the prognosis of a cancer patient. The invention additionally provides methods of modulating apoptosis using Bcl-G polypeptides, encoding nucleic acids, or compounds that modulate the activity or expression of Bcl-G polypeptides. The methods for modulating apoptosis can be used to treat diseases such as cancer.Type: GrantFiled: December 14, 2000Date of Patent: December 29, 2009Assignee: Burnham Institute for Medical ResearchInventors: John C. Reed, Adam Godzik, Bin Guo
-
Patent number: 7632824Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of Mcl-1 in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.Type: GrantFiled: March 16, 2007Date of Patent: December 15, 2009Assignee: Isis Pharmaceuticals, Inc.Inventor: Susan M. Freier
-
Patent number: 7632938Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for SOD1.Type: GrantFiled: October 29, 2007Date of Patent: December 15, 2009Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Patent number: 7629321Abstract: Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2?-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein “ds” indicates the RNase's specificity for certain double-stranded RNA substrates.Type: GrantFiled: October 25, 2002Date of Patent: December 8, 2009Assignee: Isis Pharmaceuticals, Inc.Inventor: Stanley T. Crooke
-
Patent number: 7626007Abstract: Disclosed herein is an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1. The isolated polypeptide binds to the DNA binding domain located from ?550 to ?487 in the promoter of the human TNF-? gene. Additionally, the level of the mRNA transcript encoding the isolated polypeptide is substantially increased in response to LPS stimulation in cultured THP-1 cells.Type: GrantFiled: April 2, 2003Date of Patent: December 1, 2009Assignee: Trustees of Boston UniversityInventor: Salomon Amar
-
Patent number: 7618947Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided.Type: GrantFiled: August 25, 2005Date of Patent: November 17, 2009Assignee: Isis Pharmaceuticals, Inc.Inventors: Eric G. Marcusson, Scott W. Henry, Youngsoo Kim, Kenneth W. Dobie
-
Patent number: 7615540Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.Type: GrantFiled: August 25, 2006Date of Patent: November 10, 2009Assignee: CoDaTherapeutics, Ltd.Inventors: Richard Colin Green, David Laurence Becker
-
Patent number: 7611883Abstract: The invention relates to a system for stable maintenance of a plasmid, to host cells for use in this system and to methods of using the system to obtain a plasmid useful in medical applications. In particular, the invention provides transformed host cell containing: i) a chromosomal gene which inhibits cell growth; and ii) a plasmid encoding an antisense sequence, wherein the antisense sequence encoded by the plasmid inhibits the action of the chromosomal gene, thereby permitting cell growth and a method for stable maintenance of a plasmid in a host cell in vivo.Type: GrantFiled: November 22, 2004Date of Patent: November 3, 2009Assignee: Cobra Biologics LimitedInventor: Rocky Marc Cranenburgh
-
Patent number: 7605252Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR.Type: GrantFiled: October 26, 2007Date of Patent: October 20, 2009Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Patent number: 7601700Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.Type: GrantFiled: August 1, 2008Date of Patent: October 13, 2009Assignees: Eli Lilly and Company, ISIS Pharmaceuticals, Inc.Inventors: Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
-
Patent number: 7598370Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PLK-1.Type: GrantFiled: June 15, 2007Date of Patent: October 6, 2009Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Patent number: 7595388Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to EPHA3.Type: GrantFiled: June 5, 2007Date of Patent: September 29, 2009Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Patent number: 7592324Abstract: RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; ?1- and ?2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.Type: GrantFiled: February 1, 2006Date of Patent: September 22, 2009Assignee: Alcon, Inc.Inventors: Allan R. Shepard, Jon E. Chatterton, Abbot F. Clark, Martin B. Wax
-
Patent number: 7592444Abstract: Efficient sequence specific gene silencing of myeloid cell leukemia sequence 1 is possible through the use of siRNA technology. By selecting particular siRNAs directed to myeloid cell leukemia sequence 1 by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.Type: GrantFiled: February 11, 2009Date of Patent: September 22, 2009Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
-
Patent number: 7589074Abstract: A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for identifying pharmaceutical lead compounds capable of modulating cellular functions of cadherin-11 such as cell proliferation, apoptosis, factor secretion, and binding of cadherin-11 to cadherin-11 counter-receptor inhibiting binding of cadherin-11 to its counter-receptor either in the context of a cell or in soluble form.Type: GrantFiled: November 21, 2007Date of Patent: September 15, 2009Assignee: The Brigham and Women's Hospital, Inc.Inventors: Michael B. Brenner, Xavier Valencia
-
Patent number: 7582747Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for INCENP.Type: GrantFiled: June 6, 2008Date of Patent: September 1, 2009Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Patent number: 7582746Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for C3.Type: GrantFiled: October 26, 2007Date of Patent: September 1, 2009Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Patent number: 7579329Abstract: The present invention provides a novel all-trans-RA inducible all-trans-RA metabolizing cytochrome P450, P450RAI-2, that is predominantly expressed in the brain, cerebellum in particular. It is also expressed in normal and tumour lung tissue and in breast cancer cells and may have a correlation with lung and breast cancer. Human P450RAI-2 show 42% amino acid identity to human P450RAI-1 and when transfected into COS-1 cells causes the rapid conversion of all-trans-RA into more polar metabolites including the inactive products 4-oxo-RA, 4-OH-RA and 18-OH-RA. P450RAI-2, as with P450RAI-1, is also inducible in certain cultured cell lines exposed to all-trans-RA. Methods for and uses of the new polynucleotide, polypeptide, fragments thereof and inhibitors thereof, include the treatment of dermatological disorders, cancer and certain brain disorders.Type: GrantFiled: August 3, 2006Date of Patent: August 25, 2009Assignee: Cytochroma Inc.Inventors: Jay A. White, Martin P. Petkovich, Glenville Jones, Heather Ramshaw